Navigation Links
Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
Date:10/21/2011

CORAL SPRINGS, Fla., Oct. 21, 2011 /PRNewswire/ -- Boca Pharmacal, Inc., today announced that it has received approval from the FDA of its Abbreviated New Drug Application (ANDA) for Glycopyrrolate Tablets USP, 1 mg and 2 mg, the generic version of Robinul Tablets, 1 mg and Robinul Forte Tablets, 2 mg, distributed by Shionogi Pharma, Inc. Glycopyrrolate tablets are intended for use as adjunctive therapy in the treatment of peptic ulcers.

"We're up to our third approval this year," said Robert Edwards, CEO of Boca Pharmacal.  "Each approval – including Glycopyrrolate Tablets – has been consistent with our mission to pursue and provide products to the marketplace that are important to our customers, but may be overlooked by some of the huge multinationals. We're continuing to file new ANDAs, and will keep doing so in our ongoing effort to provide the generic products our customers – and their patients – need."

Boca Pharmacal, Inc.

Since its beginnings in 1998, Boca Pharmacal's mission has been to offer niche items that were overlooked by some of the larger generic companies as affordable alternatives to brand-named products.

Using multiple facilities across the globe, Boca Pharmacal has a broad reach and a reliable vertical structure that allows them to develop products that include tablets and capsules, semi-solids, solutions, and suspensions. They continue to invest in research and development to make sure they're providing their clients with a wide variety of offerings. The Boca Pharmacal product line is marketed to chains, wholesalers, distributors, managed markets and government agencies.  Boca Pharmacal is located at 3550 NW 126th Avenue, Coral Springs, Florida, 33065. For more information visit www.bocapharmacal.com.CONTACT:

Jennifer MouraBoca Pharmacal3550 NW 126th AveCoral Springs, FL 33065Phone: (954) 346-8810Email: info@bocapharmacal.com
'/>"/>

SOURCE Boca Pharmacal, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Mission Pharmacal Launches CitraNatal(R) Assure Prescription Prenatal Vitamin
2. Mission Pharmacal Launches New Vitamin B6-Rich Prescription Prenatal Vitamin, CitraNatal(R) B-Calm
3. Nautilus Neurosciences and Mission Pharmacal Announce Exclusive Co-Promotion Agreement for CAMBIA™ (diclofenac potassium for oral solution) for the Acute Treatment of Migraine to the Womens Health Market
4. Boca Pharmacal Receives FDA Approval for Hydrocodone Bitartrate and Acetaminophen Tablets
5. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
6. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
7. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
8. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
9. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
10. CryoCor Receives FDA Approval for Right Atrial Flutter
11. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... , April 20, 2017 Research and ... Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, ... report to their offering. ... The global pharmacogenomics market was valued at US$ 7,167.6 Mn ... by 2024, expanding at a CAGR of 5.6% from 2016 ...
(Date:4/20/2017)... April 20, 2017 NeuroVive Pharmaceutical AB ... announced positive preclinical results demonstrating anti-fibrotic effects ... non-alcoholic steatohepatitis (NASH), in an additional well-validated ... NV556 has previously shown similar anti-fibrotic effects ... NeuroVive,s scientists present novel data demonstrating anti-fibrotic ...
(Date:4/19/2017)... 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE MKT: CRHM) (the ... Co. Healthcare Investor Conference 2017 at the Sheraton Hotel in ... Chief Executive Officer of the Company is scheduled to present on ... Bear and the Chairman of the Board, Tony Holler ... ...
Breaking Medicine Technology:
(Date:4/26/2017)... ... April 26, 2017 , ... Datos Health , ... partnership with Med-e-Mass , the largest Electronic Medical Records (EMR) provider in South ... care plan incentives to a patient’s remote health progress, empowering the patient to take ...
(Date:4/26/2017)... ... April 26, 2017 , ... Infertility may be ... conditions and has helped many women become pregnant upon treating their diagnosis. ... and simple outpatient evaluations. We can provide the necessary information to diagnose ...
(Date:4/26/2017)... ... April 26, 2017 , ... Want to learn more about ... ) that demonstrates how this advanced plant breeding technology is a more efficient ... fewer resources. It highlights the business’ principles, research and collaboration efforts in this ...
(Date:4/26/2017)... ... April 26, 2017 , ... ... is proud to announce that it has received 510(k) clearance from the U.S. ... Home and the MyoCycle Pro. , Both devices are stationary cycling systems that ...
(Date:4/25/2017)... , ... April 25, 2017 , ... ... have signed an agreement to be the preferred physical therapy provider for Derby ... returning them to Derby City CrossFit as quickly and effectively as possible, ProRehab’s ...
Breaking Medicine News(10 mins):